Proprotein convertase subtilisin/kexin type 9 (PCSK9) in lipid metabolism, atherosclerosis and ischemic stroke

PCSK9: From discovery to therapeutic applications

(2014) Michel Farnier   Archives of Cardiovascular Diseases

Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials

(2014) Helen M Colhoun et al.   BMC Cardiovascular Disorders

Plasma PCSK9 levels are associated with the severity of coronary stenosis in patients with atherosclerosis

(2014) Sha Li et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Influence of PCSK9 polymorphisms on plasma lipids and response to atorvastatin treatment in Brazilian subjects

(2014) Jacqueline M. Anderson et al.   Journal of Clinical Lipidology

Effect of E670G Polymorphism in PCSK9 Gene on the Risk and Severity of Coronary Heart Disease and Ischemic Stroke in a Tunisian Cohort

(2014) Afef Slimani et al.   JOURNAL OF MOLECULAR NEUROSCIENCE

PCSK9 is Present in Human Cerebrospinal Fluid and is Maintained at Remarkably Constant Concentrations Throughout the Course of the Day

(2014) Yan Q. Chen et al.   LIPIDS

Guideline-Directed Low-Density Lipoprotein Management in High-Risk Patients With Ischemic Stroke

(2014) Gustavo Saposnik et al.   STROKE

Correlation of PCSK9 Gene Polymorphism with Cerebral Ischemic Stroke in Xinjiang Han and Uygur Populations

(2014) Jing Lei   MEDICAL SCIENCE MONITOR

Low-density lipoprotein subfraction, carotid artery intima-media thickness, nitric oxide, and tumor necrosis factor alpha are associated with newly diagnosed ischemic stroke

(2013) MedineCumhur Cure et al.   Annals of Indian Academy of Neurology

The safety of therapeutic monoclonal antibodies: Implications for cardiovascular disease and targeting the PCSK9 pathway

(2013) A.L. Catapano et al.   ATHEROSCLEROSIS

Bad cholesterol breaking really bad

(2013) T. C. Nichols   BLOOD

Immune Effector Mechanisms Implicated in Atherosclerosis: From Mice to Humans

(2013) Peter Libby et al.   IMMUNITY

The Year in Atherothrombosis

(2013) Javier Sanz et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Targeting the Proprotein Convertase Subtilisin/Kexin Type 9 for the Treatment of Dyslipidemia and Atherosclerosis

(2013) Daniel Urban et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Secondary stroke prevention

(2013) Graeme J Hankey   LANCET NEUROLOGY

Differential effects of PCSK9 loss of function variants on serum lipid and PCSK9 levels in Caucasian and African Canadian populations

(2013) Janice Mayne et al.   Lipids in Health and Disease

Decreased APOE-containing HDL subfractions and cholesterol efflux capacity of serum in mice lacking Pcsk9

(2013) Seungbum Choi et al.   Lipids in Health and Disease

Association of serum proprotein convertase subtilisin/kexin type 9 with carotid intima media thickness in hypertensive subjects

(2013) Chan Joo Lee et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Epidemiology of stroke and its subtypes in Chinese vs white populations: A systematic review

(2013) C.-F. Tsai et al.   NEUROLOGY

PCSK9 Prosegment Chimera as Novel Inhibitors of LDLR Degradation

(2013) Yascara Grisel Luna Saavedra et al.   PLoS One

Effect of mutations in LDLR and PCSK9 genes on phenotypic variability in Tunisian familial hypercholesterolemia patients

(2012) Afef Slimani et al.   ATHEROSCLEROSIS

Identification and characterization of new gain-of-function mutations in the PCSK9 gene responsible for autosomal dominant hypercholesterolemia

(2012) Marianne Abifadel et al.   ATHEROSCLEROSIS

Gene Inactivation of Proprotein Convertase Subtilisin/Kexin Type 9 Reduces Atherosclerosis in Mice

(2012) Maxime Denis et al.   CIRCULATION

Proprotein convertase subtilisin/kexin type 9 inhibition

(2012) David A. Marais et al.   CURRENT OPINION IN LIPIDOLOGY

Regulation of Epithelial Sodium Channel Trafficking by Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)

(2012) Vikas Sharotri et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The biology and therapeutic targeting of the proprotein convertases

(2012) Nabil G. Seidah et al.   NATURE REVIEWS DRUG DISCOVERY

Exploring the interaction between SNP genotype and postmenopausal hormone therapy effects on stroke risk

(2012) Ying Huang et al.   Genome Medicine

Circulating Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Regulates VLDLR Protein and Triglyceride Accumulation in Visceral Adipose Tissue

(2011) Anna Roubtsova et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels

(2011) Nicola Ferri et al.   ATHEROSCLEROSIS

Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH

(2011) Paola Lo Surdo et al.   EMBO REPORTS

PCSK9 siRNA inhibits HUVEC apoptosis induced by ox-LDL via Bcl/Bax–caspase9–caspase3 pathway

(2011) Chun-Yan Wu et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

A Prospective Natural-History Study of Coronary Atherosclerosis

(2011) Gregg W. Stone et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Unique MicroRNA Signature Associated With Plaque Instability in Humans

(2011) Francesco Cipollone et al.   STROKE

Effects of the Prosegment and pH on the Activity of PCSK9

(2010) Suzanne Benjannet et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack

(2010) Karen L. Furie et al.   STROKE

Effects of PCSK9 variants on common carotid artery intima media thickness and relation to ApoE alleles

(2009) Giuseppe Danilo Norata et al.   ATHEROSCLEROSIS

PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities

(2009) Majambu Mbikay et al.   FEBS LETTERS

Antagonism of Secreted PCSK9 Increases Low Density Lipoprotein Receptor Expression in HepG2 Cells

(2009) Markey C. McNutt et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Degradation of LDLR protein mediated by ‘gain of function’ PCSK9 mutants in normal and ARH cells

(2008) Tommaso Fasano et al.   ATHEROSCLEROSIS

PCSK9 as a therapeutic target of dyslipidemia

(2008) Nabil G Seidah   EXPERT OPINION ON THERAPEUTIC TARGETS

Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor

(2008) D.-W. Zhang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA